ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,229.99
-1.19%
Dow Jones
42,063.36
0.09%
Gold vs US Dollar
2,622.30
0.00%
Brent Oil
74.135
0.00%
Bitcoin
63,055.45
-0.23%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
Unknown symbol
Date:
Sort by:
DateTimeSourceHeadlineSymbolCompany
21/09/202402:00PR Newswire (US)European Wellness Unveils Premier Medical Wellness Center in Kota Kinabalu, Sabah: A Landmark in Global Healthcare
21/09/202402:00PR Newswire (US)European Wellness Unveils Premier Medical Wellness Center in Kota Kinabalu, Sabah: A Landmark in Global Healthcare
21/09/202401:45PR Newswire (US)Greenberg Traurig Advises OPKO Health in $237.5 Million Asset Sale to Labcorp
21/09/202401:36PR Newswire (US)Niutech at the Forefront: U.S.-China Circular Economy Forum Tackles "White Pollution"
21/09/202401:15PR Newswire (US)Preclinical Research with Advanced Oncology Models and Immuno-oncology Services by Altogen Labs
21/09/202401:00PR Newswire (US)SHK Law Investigates Legal Implications of Negligence in Connection with the Airport Fire
21/09/202401:00PR Newswire (US)Curious Yellow Shield Pops Up Across The Streets of Seoul's Hongdae and Itaewon Neighbourhoods
21/09/202400:39PR Newswire (US)Global Ultrasound Institute Launches GUSI Fellowships Platform: Elevating Point-of-Care Ultrasound Education
21/09/202400:23PR Newswire (US)Germany's Wehlener Sonnenuhr Recognized as One of the 10 Greatest Vineyards in the World
21/09/202400:14PR Newswire (US)South Coast AQMD Expands Lawn & Garden Incentive Program
21/09/202400:09PR Newswire (US)Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar AtaxiaNYSE:BHVNBiohaven Ltd
21/09/202400:00PR Newswire (US)TeraBox Celebrates 2nd Anniversary of Its Massively Popular Referral Program
21/09/202400:00PR Newswire (US)TeraBox Celebrates 2nd Anniversary of Its Massively Popular Referral Program
20/09/202423:48PR Newswire (US)Revolutionizing Fertilizer with Sustainable Solutions
20/09/202423:44PR Newswire (US)Keuka College Notifies Individuals of Data Security Incident
20/09/202423:36UK RegulatoryCommuniqué de presse : Approbation du Sarclisa aux États-Unis : premier anti-CD38, en association avec un traitement conventionnel, pour les patients atteints d’un myélome multiple nouvellement diagnostiqué (...)EU:SANSanofi
20/09/202423:36UK RegulatoryCommuniqué de presse : Approbation du Sarclisa aux États-Unis : premier anti-CD38, en association avec un traitement conventionnel, pour les patients atteints d’un myélome multiple nouvellement diagnostiqué (...)BIT:SANFSanofi
20/09/202423:36UK RegulatoryCommuniqué de presse : Approbation du Sarclisa aux États-Unis : premier anti-CD38, en association avec un traitement conventionnel, pour les patients atteints d’un myélome multiple nouvellement diagnostiqué (...)TG:SNWSanofi
20/09/202423:36UK RegulatoryPress Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplantBIT:1SANSanofi
20/09/202423:36UK RegulatoryPress Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplantEU:SANSanofi
20/09/202423:36UK RegulatoryPress Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplantBIT:SANFSanofi
20/09/202423:36UK RegulatoryPress Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplantTG:SNWSanofi
20/09/202423:36UK RegulatoryCommuniqué de presse : Approbation du Sarclisa aux États-Unis : premier anti-CD38, en association avec un traitement conventionnel, pour les patients atteints d’un myélome multiple nouvellement diagnostiqué (...)BIT:1SANSanofi
20/09/202423:00PR Newswire (US)Muskogee City County Enhanced 911 Trust Authority Provides Notice of Security Incident 
20/09/202423:00PR Newswire (US)CREATOR OF THE CHOSEN ANNOUNCES THE LAUNCH OF NEW PRODUCTION COMPANY 5&2 STUDIOS DURING CHOSENCON IN ORLANDO
20/09/202422:50PR Newswire (US)The Voice Assistant Application Market is set to grow by USD 21.94 Billion from 2024-2028, driven by digital transformation and AI-powered market evolution - Technavio
20/09/202422:45PR Newswire (US)The Soft Tissue Repair Market is expected to grow by USD 3.29 billion from 2024-2028, driven by rising accidental injuries and AI's impact on market trends - Technavio
20/09/202422:45PR Newswire (US)City of Ontario Announces "Ontario Sports Empire" as Name for Largest Multi-Use Sports Complex on West Coast
20/09/202422:45PR Newswire (US)Aequitas Solutions Introduces Application and Lottery Module
20/09/202422:35PR Newswire (US)Smart Shoes Market to Grow by USD 984.9 Million (2024-2028) as Product Innovation and Premiumization Drive Revenue, with AI Powering Market Transformation - Technavio

Your Recent History

LSE
THG
Thg
LSE
GMR
Gaming Realms
LSE
SFOR
S4 Capital
LSE
FLTR
Flutter Entertainment
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved